Shanghai MicroPort MedBot (Group) Co., Ltd. Class H (HK:2252) has released an update.
Shanghai MicroPort MedBot (Group) Co., Ltd. anticipates a significant revenue surge of approximately 103% to 108% year-on-year for the first half of 2024, propelled by robust domestic sales of its Toumai laparoscopic surgical robot and successful overseas expansion, including its first EU CE-certified installations. The company’s revenue boost is also aided by the global reach of its SkyWalker orthopedic surgical robot and the introduction of new products like the R-ONE vascular interventional robot. While the final interim results are pending, the announcement serves as a preliminary indicator for shareholders and potential investors.
For further insights into HK:2252 stock, check out TipRanks’ Stock Analysis page.
